Skip to main content
Karo Pharma AB logo

Karo Pharma AB — Investor Relations & Filings

Ticker · KARO ISIN · SE0007464888 LEI · 213800G54Z51LOPGTA79 ST Manufacturing
Open in API
Filings indexed 653 across all filing types
Latest filing 2012-04-02 M&A Activity
Country SE Sweden
Listing ST KARO

About Karo Pharma AB

https://www.karohealthcare.com/

Karo Pharma AB, operating as Karo Healthcare, is a healthcare company that develops, markets, and sells a broad portfolio of everyday healthcare products. The company's offerings are designed to prevent illness and treat common health problems, empowering consumers to manage their daily well-being. The portfolio consists of various branded medicines and consumer healthcare products distributed through pharmacies and directly to healthcare providers. With products available in over 90 countries, the company focuses on becoming a leading force in its sector by employing a consumer-centric approach, strategic innovation, and omnichannel excellence.

Recent filings

Filing Released Lang Actions
COLLABORATION WITH ZYDUS CADILA EXPIRES – KARO BIO CONTINUES TO DEVELOP SAFER GLUCOCORTICOIDS
M&A Activity Classification · 99% confidence The document is a press release dated April 2, 2012, announcing the expiration of a collaboration agreement between Karo Bio and Zydus Cadila regarding glucocorticoid research and development. It details the strategic decision to pursue different development paths and mentions the company's focus on a new mechanism. This type of announcement, which details strategic shifts, partnership outcomes, or pipeline updates outside of routine financial reporting (like earnings or annual reports), typically falls under general corporate news or regulatory filings. Since it is not a specific financial report (10-K, IR, ER), a management change (MANG), or a transaction (POS, TAR), and it is a formal announcement published according to securities laws, it best fits the general 'Regulatory Filings' category (RNS) as a significant corporate event announcement, or potentially a general 'LTR' if it were related to legal matters, but here it is purely strategic/operational news release. Given the options, RNS is the most appropriate fallback for a significant, non-standard corporate announcement that isn't explicitly covered elsewhere.
2012-04-02 English
CHANGED DATE FOR THE ANNUAL GENERAL MEETING AND NOTICE TO EXTRAORDINARY GENERAL MEETING OF KARO BIO
AGM Information Classification · 99% confidence The document is explicitly titled "NOTICE OF EXTRAORDINARY GENERAL MEETING OF KARO BIO AB (PUBL)". It details the date, time, location, and procedures for shareholders to attend and vote at this meeting. It also outlines the specific proposals to be voted upon, such as amending the Articles of Association and reducing share capital. This content directly relates to the formal proceedings and materials associated with a shareholder meeting, fitting the definition of AGM Information (AGM-R). Although it mentions an 'extraordinary' meeting, the core function aligns best with AGM-R, which covers presentations and materials shared during the Annual General Meeting (and by extension, related general meetings). It is not a full 10-K, an ER, or a simple RPA, as it contains the substantive notice and agenda proposals.
2012-03-23 English
ÄNDRAT DATUM FÖR ÅRSSTÄMMA OCH KALLELSE TILL EXTRA BOLAGSSTÄMMA I KARO BIO
AGM Information Classification · 99% confidence The document is titled "KALLELSE TILL EXTRA BOLAGSSTÄMMA I KARO BIO AB (PUBL)", which translates to 'Notice of Extraordinary General Meeting in Karo Bio AB (publ)'. It details the date, time, location, registration requirements, proposed agenda items (including capital reduction due to losses and changes to the articles of association), and information availability for shareholders regarding an upcoming meeting. This content directly corresponds to the purpose of a notice for a shareholder meeting, which is often covered by Proxy Solicitation & Information Statement (PSI) or, given the context of a formal meeting notice, sometimes falls under AGM-R if it were the Annual General Meeting, but since it is an *Extra* General Meeting (EGM) notice detailing voting matters, PSI is a strong candidate. However, the definitions provided do not explicitly cover EGM notices. Given the focus on calling shareholders to a meeting and providing necessary information for voting on specific corporate actions (like capital changes), it is most closely related to shareholder meeting materials. Since the document is a formal notice calling for a vote, and not the actual voting results (DVA) or the presentation materials (AGM-R, which is for the Annual General Meeting), PSI (Proxy Solicitation & Information Statement) is the best fit as it covers materials sent to shareholders to provide information and request votes for meetings. The document is comprehensive, not a short announcement of a report, so RPA/RNS is unlikely.
2012-03-23 Swedish
KARO BIO LAYS OFF 16 EMPLOYEES
Regulatory Filings Classification · 95% confidence The document is a short press release dated February 21, 2012, announcing layoffs and resulting cost savings (MSEK 17 annually). It is not a comprehensive financial report (like 10-K or IR), nor is it a specific regulatory filing like Director's Dealing (DIRS) or a Dividend Notice (DIV). It relates to internal operational changes and cost reduction measures. Since it does not fit the specific categories like ER, CT, or MANG (which is for board/senior management changes, not general layoffs), and it is a general corporate announcement, the most appropriate fallback category is Regulatory Filings (RNS), as it is a mandatory disclosure under Swedish securities law ('Karo Bio publishes this information in accordance with the Swedish Securities Markets Act').
2012-02-21 English
KARO BIO SÄGER UPP 16 MEDARBETARE
Regulatory Filings Classification · 95% confidence The document is a short press release dated February 21, 2012, announcing staff reductions ('säger upp 16 medarbetare') to reduce costs. It includes contact information and a brief 'About Karo Bio' section. Crucially, it ends with a statement that the information is what Karo Bio is obligated to disclose under securities market laws and that the press release is available on their website and a news distribution service. Since this is a short, specific operational announcement that doesn't fit clearly into financial reporting (10-K, IR, ER) or governance (DEF 14A, DVA), and it functions as a general regulatory disclosure, the most appropriate classification is the general regulatory announcement fallback category, RNS (Regulatory Filings). It is not a report itself, but an announcement of an operational event.
2012-02-21 Swedish
KARO BIO AVBRYTER EPROTIROME-PROGRAMMET
Legal Proceedings Report Classification · 99% confidence The document is a press release dated February 14, 2012, announcing that Karo Bio AB has decided to terminate its Phase III program for eprotirome due to adverse findings in a long-term animal study. It details the reasons for termination, the financial implications (write-down costs), and the resulting strategic shift (canceling the planned spin-off and focusing on preclinical projects). This type of announcement, detailing a major operational decision, financial impact, and strategic change, is characteristic of a general corporate announcement or regulatory filing that doesn't fit the specific financial report categories (like 10-K, IR, ER). Since it is a significant, non-standard announcement that is not a specific financial report, dividend notice, or management change, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for important corporate news releases not covered elsewhere. It is not an Earnings Release (ER) as it focuses on a program termination, nor is it a Call Transcript (CT) or Investor Presentation (IP). Given the content is a formal announcement of a major business decision, RNS is the best fit among the provided options.
2012-02-14 Swedish

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.